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AbstrACt 
Purpose The currently ongoing Epidemiological Strategy 
and Medical Economics (ESME) research programme 
aims at centralising real-life data on oncology care for 
epidemiological research purposes. We draw on results 
from the metastatic breast cancer (MBC) cohort to 
illustrate the methodology used for data collection in the 
ESME research programme.
Participants All consecutive ≥18 years patients with MBC 
treatment initiated between 2008 and 2014 in one of the 
18 French Comprehensive Cancer Centres were selected. 
Diagnostic, therapeutic and follow-up data (demographics, 
primary tumour, metastatic disease, treatment patterns 
and vital status) were collected through the course of the 
disease. Data collection is updated annually.
Finding to date With a recruitment target of 30 000 
patients with MBC by 2019, we currently screened a 
total of 45 329 patients, and >16 700 patients with a 
metastatic disease treatment initiated after 2008 have 
been selected. 20.7% of patients had an hormone 
receptor (HR)-negative MBC, 73.7% had a HER2-negative 
MBC and 13.9% were classified as triple-negative BC (ie, 
HER2 and HR status both negative). Median follow-up 
duration from MBC diagnosis was 48.55 months for the 
whole cohort.
Future plans These real-world data will help standardise 
the management of MBC and improve patient care. A 
dozen of ancillary research projects have been conducted 
and some of them are already accepted for publication 
or ready to be issued. The ESME research programme is 
expanding to ovarian cancer and advanced/metastatic lung 
cancer. Our ultimate goal is to achieve a continuous link to 
the data of the cohort to the French national Health Data 
System for centralising data on healthcare reimbursement 
(drugs, medical procedures), inpatient/outpatient stays and 
visits in primary/secondary care settings.
trial registration number NCT03275311; Pre-results. 
strengths and limitations of this study
 ► The Epidemiological Strategy and Medical 
Economics research programme aims at centralis-
ing real-life data on oncology care for epidemiolog-
ical research purposes.  The ongoing screening of 
the metastatic breast cancer (MBC) cohort reached 
>16 700 patients with metastatic disease treatment 
initiated after 2008, currently contributing to the de-
velopment of one of the most important cohort of 
patients with treated MBC.
 ► Screening process of patients and data collection 
(diagnostic, therapeutic and follow-up data) through 
the course of the disease provide a solid base of 
knowledge for real-world survival.  The significant 
resources deployed allowed to achieve a high qual-
ity-level data validation, including systematic con-
sultancy of the source folder for data collection, and 
the implementation of effective quality control, and 
regular audit.
 ► The main limitations are (1) the lack of availabili-
ty of electronic medical records data required to 
describe the global MBC management due to the 
low level of standardisation of current electronic 
medical records and (2) the retrospective patient 
selection—data collection, notwithstanding the pro-
spective compilation of real-life follow-up, clinical 
and biological events, preventing to assess several 
endpoints classically defined for randomised clini-
cal trials such as progression disease at predefined 
time points.
 ► Despite the current large-scale recruitment of 
patients and greater than one-third of French pa-
tients with MBC managed in French Comprehensive 
Cancer Centres, future studies should integrate the 
diversity of management options adopted in any 
health institutions. 
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bACkground 
Real-world evidence (RWE) studies and observational 
studies using real-world data (RWD) play a growing role in 
conducting comparative effectiveness research on phar-
maceutical products and other healthcare interventions. 
They aim to bridge the gap between the highly controlled 
environment of randomised clinical trials (RCTs) and 
real-life clinical practice.1 In particular, health authorities 
are interested in gathering RWD for long-term benefit–
risk assessment and, increasingly, health economic eval-
uations for reimbursement decisions.2 With their high 
internal validity, RCTs are considered the gold standard 
of evidence for establishing treatment efficacy, although 
the generalisability of findings to clinical practice may 
be limited.3 In fact, cancer survival endpoints in the 
real-life setting may differ from that measured in tradi-
tional RCTs.4 Furthermore, other limitations such as 
short follow-up and small sample size have created uncer-
tainty in estimating survival criteria in RCTs, and thus 
surrogate endpoints are generally used such as progres-
sion-free survival (PFS) or time to progression.5 On the 
other hand, large population-based cohorts with longer 
follow-up periods can be particularly appropriate to assess 
long-term clinical outcomes, such as overall survival (OS) 
outside of the RCT setting6 and to detect changes in 
medical practice.
RWE and observational studies are non-experimental 
research where cancer management (treatments and 
disease evolution assessment) is left to the choice of care 
providers and patients.7 Over the past few years, a broad 
consensus arose around the requirement for high-quality 
data from large cohorts to strengthen and drive improve-
ments in research methods and practices.8 The goal of 
these studies is to generate complementary information 
to RCTs based on larger samples and provide answers 
regarding particular populations in real-life clinical 
practice. These studies are more prone to biases such as 
baseline differences between patients (selection bias) or 
bias due to confounding by indication for example. To 
minimise sources of such biases, statistical approaches 
including adjusted analyses, propensity score methods or 
instrumental variables may be also employed.9–12
Metastatic breast cancer (MBC) is one of the leading 
causes of cancer-related mortality among women in 
Western countries.13 A relatively high proportion (approx-
imately 30%) of patients with breast cancer develop meta-
static disease,14 and while significant treatment advances 
have been made, the overall prognosis is poor with a 5-year 
survival rate of 25%.15 The national academic network 
of cancer centres in France (French Comprehensive 
Cancer Centres (FCCCs)), which together handle over 
one-third of all breast cancer cases nationally, decided to 
launch in 2014 a programme dedicated to focusing on 
RWD in oncology databases in MBC through Epidemio-
logical Strategy and Medical Economics (ESME) research 
programme.
The ESME research programme aims to build a compre-
hensive database on oncology care for epidemiological 
research purposes to improve knowledge on medical 
practice in real-life setting, on public health and health-
care use, and to provide information to health authorities 
and other associated bodies.
Several studies based on real-life data collection have 
been developed in this programme. Different cohorts of 
patients with ovarian cancer and patients with advanced/
metastatic lung cancer are currently recruiting.
Some results from the ongoing ESME MBC project ( 
ClinicalTrials. gov NCT03275311) whose aim is to describe 
the medical care of patients treated for MBC according to 
their disease characteristics the evolution of their meta-
static disease and their outcomes have been recently 
published. Recent analyses explored OS in different 
subgroups of patients with MBC, and first-line therapy in 
patients with HER2-negative MBC, and in patients with 
hormone receptor-positive HER2-negative MBC.16–18
In this paper, we describe the methodological princi-
ples that underpin the ESME research programme, and 
illustrate this innovative approach through this first ESME 
MBC cohort. Design, brief description of the selected 
population and current status are reported.
Methods
The ESME MBC cohort is a population-based registry in 
18 FCCCs (http://www. unicancer. fr/ en/ rd- unicancer/ 
esme), which collected data on all consecutive patients 
treated for MBC from 2008. Annual data collection 
phases are planned to add new diagnosed cases and 
update patients’ follow-up data.
study PoPulAtion
eligibility criteria
Patients eligible to the ESME MBC cohort were male 
or female patients aged ≥18 years with MBC whose first 
metastasis had been either completely or partially treated 
between 1 January 2008 and 31 December 2014 in one of 
the FCCCs. MBC treatment could include radiotherapy, 
chemotherapy, targeted therapy, immunotherapy or 
endocrine therapy.
Patient screening process
Patient screening process involved two steps: an auto-
mated case screening followed by the validation of selec-
tion for each screened case. The automated case screening 
was based on information retrieved from multiple data 
sources available within each FCCC: administrative 
records (French National Computerised Medical Infor-
mation System) (via MBC-specific International Classifi-
cation of Diseases (ICD) codes associated with inpatient 
stays), pharmacy records, patient medical records (PMRs), 
including multidisciplinary team meeting records and 
search using relevant keywords, MBC-specific registries.
The objective of the first step—automated screening 
step—was to identify all cases with inpatient stays or thera-
peutic management for MBC in one of the FCCCs during 
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the selection period and generate the patient screening 
list. The ICD codes used were C50 (Malignant neoplasm of 
breast), C77.- (except C77.3) (Secondary and unspecified 
malignant neoplasm of lymph nodes), C78.- (Secondary 
malignant neoplasm of respiratory and digestive organs) 
and C79.- (Secondary malignant neoplasm of other and 
unspecified sites). Once the patient screening list was 
finalised in each centre, data were subsequently anony-
mised and each patient had been assigned an ESME 
number. The first screening step did not allow to precisely 
identify the date for first MBC-specific treatment, and 
the second step was performed to cross-check eligibility 
criteria for all screened cases and specify the dates related 
to the initiation of the MBC first-line treatment, using 
data from the PMRs.
Patient data protection
The ESME research programme was managed by R&D 
Unicancer in accordance with guidelines for Good Phar-
macoepidemiology Practices and Good Epidemiology 
Practices.19 20
Ancillary projects analyses were notified to an indepen-
dent ethics committee (Lyon Sud-Est II) on 17 December 
2015.
data collection
The data of the selected patients were planned to be 
collected by trained research assistants and annually 
updated. The data collection was performed in two 
phases from October 2014 to October 2016. A first data 
collection phase conducted in 2014–2015 collected 
the data from patients with MBC treatment initiated 
between 1 January 2008 and 31 December 2013 in 
one of the FCCCs. A second phase of data collection 
performed in 2016 added to the ongoing database 
the data from patients with MBC treatment initiated 
between 1 January and 31 December 2014, and follow-up 
data for the global cohort were consequently updated. 
Hence, the ongoing database provides an overview of 
all the data from patients with an MBC treatment initi-
ated from 2008; information is updated with last contact 
information available in the PMR at the date of the data 
collection.
baseline and follow-up data
The ESME MBC cohort is composed of three types of 
data set (figure 1):
Patient-related data are obtained from systematic review 
of patient medical records (non-structured data) and 
provide information on patient demographics, cancer 
family history, characteristics of primary tumour, re-
lapses, metastatic recurrences pathological reports (tu-
mour size, grade, histological type), hormone-receptor 
status and HER-2 status, therapeutic care (focusing on 
cancer-related treatment) and settings, reasons for 
treatment termination and clinical events.
Hospitalisation records are integrated data from a struc-
tured and automated database related to inpatient 
stays, and primarily used to bill the French National 
Health Insurance Fund (Assurance Maladie). It pro-
vides information on patient entry and discharge in-
formation (date and destination code at discharge), 
ICD codes associated to each stay, diagnostic, medical 
Figure 1 The Epidemiological Strategy and Medical Economics (ESME) data platform. GHS, Hospital stay related group.
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and therapeutic procedures including radiotherapy 
and surgery.
Pharmacy-dispensed treatment records includes all data 
related to anticancer treatments obtained from each 
centre’s pharmacy database: drugs (International 
Non-proprietary Name), administration date, protocol 
name, patient’s height and body mass index, cycle ID, 
common unit of delivery (UCD) code (pharmaceutical 
form related to the drug dosage), line of treatment and 
administration in a clinical trial (yes/no). It exclusively 
includes information on products that are prescribed 
by each FCCC.
The detailed raw data collected above and derived data 
are listed in table 1.
dAtA MAnAgeMent
Any data integrated in the ESME research programme 
are subject to quality control (QC) procedures.
Patient-related data are registered via an electronic 
case report form (eCRF) in each centre by trained clin-
ical research assistants (CRAs) between December 2014 
and October 2016. Medical support to assist CRAs was 
provided to ensure QC data and appropriate recoding 
was performed before annual database lock when 
required. All ESME procedures are handled according 
to the Guidelines for Good Pharmacoepidemiology 
Practices.20 Importantly, all data are exclusively obtained 
retrospectively; no attempts are made to recover unavail-
able data from PMRs by contacting healthcare providers 
or patients.
The clinical data management system used was SAS soft-
ware V.9.4. For both, ESME MBC database and the eCRF 
tool administration used an Oracle solution and certified 
personal data hosting system guarantee data security.
on-site quality review
On-site quality review of the patient screening process was 
carried out. This consisted of checking eligibility criteria 
on samples of selected and non-selected cases in each 
FCCC. For selected cases, key variables were crosschecked 
versus the source data. For all QC procedures, accepted 
error limits were 10% for non-selected patients and 5% 
for selected patients. A central audit was subsequently 
performed by the Unicancer Quality Assurance Depart-
ment, and an audit on data registration and generated 
screening list was also conducted at the local level.
dAtA quAlity AssurAnCe
governance structure
Three boards monitor the ESME Research programme: 
Scientific Committee, Deontology Committee and Inter-
national Advisory Board. The main role of the Scientific 
Committee is to (1) ensure that the applicable scientific 
rules are followed, (2) evaluate any ancillary projects 
Table 1 Main data recorded
Patient-related Hospitalisation-related Pharmacy record-related
Patient data Age Height
  Demographics Gender Body mass index
  Other cancer and family history Main diagnosis code (ICD code) Drug (International Non-proprietary Name)
  Menopausal status Linked diagnosis code (ICD code) Protocol
Initial tumour: Related significant diagnoses (ICD code) Cycle ID
  Diagnosis Diagnosis-related group code 
(reimbursement coding)
Pharmaceutical form and dosage
  Relapses Hospital stay-related group ID 
(reimbursement coding)
Administration date
  Histological results Entry date Line treatment number
  Medical care Discharge date Administered dose
Metastatic disease: Destination code at discharge Cumulated dose
  Diagnosis Medical procedures performed Inclusion in a clinical trial (yes/no)
  Progression Radiation therapy
  Histological results
  Therapies
  Invasive procedures related to 
metastasis
Last contact:
  Vital status
  Date of last contact/death
ICD, International Classification of Diseases.
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in compliance with defined criteria and scientific perti-
nence, and (3) monitor all the validated ancillary proj-
ects. The Deontology Committee monitors any potential 
conflicts of interest related to experts involved in the 
programme, gives recommendations that may improve 
the prevention of conflicts, provides opinions on indi-
vidual or particular situations, and potential collabo-
rations with private partners. The ESME International 
Advisory Board has a consultative role with regard to 
coherence of the scientific programme and reviews key 
international communications, formulates recommenda-
tions for publication rules or methodology and reinforces 
international academic cooperation.
dAtA AnAlysis PrinCiPles
Academic research teams or private organisations could 
propose ancillary projects.
For each accepted ancillary project, statistical analyses 
are conducted according to a detailed statistical analysis 
plan that must be reviewed by the scientific committee. 
This article does not aim at providing a comprehensive 
and exhaustive review on appropriate statistical methods 
to reduce bias related to analysis based on RWD.
A first ancillary project reported the outcomes (OS 
and PFS) following first-line paclitaxel treatment with 
or without bevacizumab.16 Other ongoing analyses of 
sensibility will better address the bias potentially found 
in real-life settings. Two analyses reported the description 
of OS in different subgroups of patients with MBC over 
the time, and results for the first-line therapy (endocrine 
therapy or chemotherapy) in hormone receptor-positive 
HER2 negative cancer subgroup, respectively.17 18 Other 
series accepted for communications (abstracts/posters) 
to major congress in 2017 reported epidemiological 
analyses (ie, impact of age at diagnosis, etc), therapeutic 
management (ie, impact of loco-regional treatment on 
OS, etc) and specific analyses for drug use in routine prac-
tice (ie, use of vinorelbine, everolimus, etoposide, etc).
Figure 2 Epidemiological Strategy and Medical Economics metastatic breast cancer (MBC) cohort: flow chart. FCCC, French 
Comprehensive Cancer Centre. 
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Different other subpopulations are currently being 
considered such as subgroups of metastatic triple-nega-
tive breast cancer, metastatic HER2-positive MBC, etc.
PAtient And PubliC involveMent stAteMent
Patients and/or public were not involved.
results And Current stAtus
In total, 16 711 out of the 45 329 patients screened were 
selected in the ESME MBC cohort (see figure 2).
The sensitivity and specificity of the three main 
screening sources used were explored. Sensitivity was 
highest for administrative records (78% vs43% for phar-
macy records, and 28% for BC-specific local registries). 
On the other hand, specificity was highest for BC-specific 
local registries (87% vs67% for pharmacy records, and 
49% for administrative records).
The main reasons for non-selection of screened 
patients were presence of non-MBC or other metastatic 
cancers (n=14 104 patients), initial MBC treatment 
received before 1 January 2008 (n=7486), and first metas-
tasis not initially treated in an FCCC (n=4239). Nine addi-
tional were excluded prior to the final database lock due 
to inconsistencies in the dates. A total of 16 702 patients 
were analysed (figure 2).
Table 2 summarises the main demographic and disease 
characteristics at the time of initial metastatic diagnosis. 
Patients were nearly all women (99.1%) with a median 
age of 61 years. Over half (56.2%) had at least visceral 
metastases present, with 30.2% having at least bone and 
non-visceral metastases, and 13.6% with skin only, or node 
only, or at least skin plus node. 20.7% of patients had an 
HR-negative MBC, 73.7% had a HER2-negative MBC and 
13.9% were classified as triple-negative BC (ie, HER2 and 
HR status both negative).
Median follow-up duration from MBC initiation treat-
ment was 48.55 months for the whole cohort (95% CI 
47.7 to 49.38).
disCussion
Retrospective analysis using RWD is likely to become 
increasingly important to ensure that medications are 
accepted by policymakers and adopted by patient practi-
tioners. The ESME Research programme is a large-scale 
initiative to provide access to RWD in oncology. This 
ongoing ESME MBC cohort currently centralises data 
from 16 711 patients.
The ESME research programme provides a unique 
opportunity to study a diverse range of topics related to 
MBC care and management in real-life settings. Indeed, 
there are many potential applications, including study 
of the factors influencing patient care (eg, cancer and 
patient characteristics), description of therapeutic strat-
egies (treatment lines and sequences of therapies, etc) 
and measurement of clinical events (disease progression, 
Table 2 Characteristics of the patients at of the date of 
metastatic disease diagnosis
Characteristic ESME MBC population (n=16 702)
Age (years)
  Mean (SD) 60.6 (13.8)
  Median (Q1–Q3 range) 61.0 (51.0–71.0)
Sex 
  Male 149 (0.9%)
  Female 16 553 (99.1%)
Histological grade* at primary tumour diagnosis
  1 1277 (10.1%)
  2 6438 (50.7%)
  3 4733 (37.3%)
Metastatic status†
  Not available 240 (1.9%)
  Missing data 2008
  De novo MBC 4763 (28.5%)
  Relapsed MBC 11 939 (71.5%)
Year of first metastatic treatment
  2008 2651 (15.9%)
  2009 2675 (16.0%)
  2010 2598 (15.6%)
  2011 2515 (15.1%)
  2012 2371 (14.2%)
  2013 2216 (13.3%)
  2014 1676 (10.0%)
Type of metastases
  Visceral 9383 (56.2%)
  Bones and not visceral 5047 (30.2%)
  Nodes only 880 (5.3%)
  Skin only 916 (5.5%)
  Skin+nodes 476 (2.8%)
Global HR status‡
  Positive 12 748 (76.3%)
  Negative 3451 (20.7%)
  Not determined 503 (3.0%)
Global HER2 status‡
  Positive 2863 (17.1%)
  Negative 12 306 (73.7%)
  Not determined 1533 (9.2%)
Triple-negative status
  Yes 2321 (13.9%)
Data are n (%) unless indicated otherwise.
*Histological grade at primary tumour diagnosis: the histological grade at 
primary tumour diagnosis is defined as the worst histological grade recorded 
within 1 month (30 days) after the initial diagnosis (primary tumour).
†MBC is considered de novo if the diagnosis of metastatic disease occurs 
within 6 months (180 days) after the initial diagnosis (primary tumour).
‡The ER or PR is considered positive if the pathology report indicates a 
‘positive’ result or considered as positive when ≥10% of cells in the sample 
are positive for ER or PR, respectively. The HER2 status is considered positive 
if the pathology report indicates for the immunohistochemistry result ‘3+’, ‘2+’ 
or not available, the result will be considered positive if the fluorescent in situ 
hybridisation or chromogenic in situ hybridisation result is positive. If two or 
more histological reports are available at the same date, the positive status 
is preferred. The global HR/HER2 status indicates the status at metastatic 
diagnosis based on histological results forms related to the primary tumour (if 
available) or metastatic sites.
ER, oestrogen receptor; ESME, Epidemiological Strategy and Medical 
Economics; MBC, metastatic breast cancer; PR, progesterone receptor status. 
7Pérol D, et al. BMJ Open 2019;9:e023568. doi:10.1136/bmjopen-2018-023568
Open access
death, persistence of treatment effect). Therefore, this 
approach allows a better characterisation of patients 
enroled in clinical trials and contributes to simulation of 
trials using appropriate statistical methodologies. Poten-
tially, these data could be used for health economics 
evaluation of management strategies for patients (eg, 
rehospitalisation and related ambulatory care), as well 
as reconstruction of healthcare trajectories through data 
modelling.
The ESME research programme includes alternative 
approaches to generate cohorts that use different types 
of RWD (clinical data, therapeutic treatment data, long-
term outcomes, health economics data) in the FCCCs 
versus existing registries in France, Europe and the USA 
(eg, SEER). It involves rigorous procedures for patient 
screening and data collection, ensuring both validity and 
reliability of data. It uses a fully retrospective approach, 
with no influence on treatment practice or interaction 
with oncologists. Unlike prospective interventional or 
observational research studies, data are not influenced 
by study design and reflect the real-life management of 
patients treated. While data recorded for the cohort are 
defined by experts in the field, the vast majority of data 
are collected by trained clinical research technicians, 
thereby minimising any potential risk of data misinterpre-
tation. As discussed above, the ESME MBC cohort offers 
a unique opportunity to study a wide range of research 
questions in a large sample. With respect to evaluation 
of treatment strategies, the database enables reliable 
estimation of survival criteria such as OS and surrogates 
endpoints (PFS, etc). OS improvement in diseases with a 
long median post-progression survival time, such as MBC, 
is a critical endpoint.21–23
The ESME MBC cohort also has several limitations. For 
example, the database relies on the collection and restruc-
turing of existing data only, that is, there is no creation of 
new data. Furthermore, apart from events reported in the 
PMR impacting therapeutic management, adverse effects 
are not routinely captured. Conceivably, further in-depth 
analysis of the data could highlight trends such as treat-
ment interruption or discontinuation due to toxicity, 
which is important from a risk management perspec-
tive. The main potential sources of bias include selection 
bias, and information bias due to differences in patient 
monitoring and non-standardised data collection. Selec-
tion bias has been taken into account by using rigorous 
selection procedures across all 18 FCCCs, and the data 
management plan and QC programme described above 
have been designed to limit information bias. Neverthe-
less, due to the retrospective data collection and the fact 
that it is based on real-life follow-up, clinical and biolog-
ical events are not evaluated at predefined time points 
(unlike in RCTs). For example, objective response, histor-
ical endpoint in RCTs, could not be assessed retrospec-
tively without a central review of existing imaging as not 
systematically documented in routine practice. The infor-
mation collected therefore depends on the frequency 
of follow-up visits and clinical and radiological exams 
prescribed by the patient’s doctor. As clinical signs are 
the only means by which disease metastasis can be iden-
tified, the number of disease progressions may be under-
estimated. With respect to the clinical event of death, all 
deaths are reported in the PMRs.
With respect to evaluation of treatment strategies, 
analysis of real-life data poses unique challenges, such 
as accounting for confounding factors between patient 
groups, although various statistical approaches can be 
used to address this, as discussed above.24
Concerning overall generalisability and applicability 
(external validity), it should be noted that the cohort 
centralises data from patients treated in specialised cancer 
centres only. FCCCs may use different clinical practices 
compared with public hospitals and private institutions, 
and thus patients from FCCCs may not be truly represen-
tative of all French patients with breast cancer. Potentially, 
data extrapolation from all French healthcare organisa-
tions could be developed with the Exhaustive National 
Health Reimbursement System (Système national d'infor-
mation inter-régimes de l'Assurance maladie).
The ESME MBC cohort aims to collect data for up to 
30 000 patients by 2019. As mentioned, future aims might 
include to continuously link our database to those from 
other institutions, such as the SNDS database for data on 
exhaustive healthcare reimbursement, and the INSEE 
database to provide vital status updates for patients lost 
to follow-up. The ESME research programme has further 
expanded to ovarian cancer and advanced/metastatic 
lung cancer. RWD from the ESME cohorts should help 
to provide medical recommendations and ultimately 
improve patient care.25
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